Composition: TFX-Thymomodulin is a family of 6 peptides, biotechnologically derived from the thymus glands of young calves.
Properties: The drug works as a substitute for the physiological functions of the thymus. With T-cell deficiency, TFX-THYMOMODULIN ® recruits immature system cells in the bone marrow and stimulates their maturation to the fully active T-cell phase in the lymphatic system. TFX-THYMOMODULIN ® increases granulopoiesis and erythropoiesis by acting on the bone marrow. The preparation can be used for all diseases with primary and secondary immune system disturbances involving T-cells which are thymus dependent and for a wide range of symptoms such as chronic viral, bacterial and fungal infections; allergic and auto-immune reactions; and certain lymphoproliferative syndromes.
Indications: All systemic diseases of the connective tissue, the nervous tissue, the muscles, the vessels and the internal organs caused by a deficient immune function of the thymus: chronic virus hepatitis, polyneuropathy, encephalopathy, auto-immune spinal cord diseases, acute dermatomyositis, allergic skin diseases, systemic lupus erythematosus, hypo and hypergammaglobulinaemias, cutaneous and organ-involved mycoses.
Contraindications: No absolute contraindications are known. Relative contraindications include: pregnancy, menstruation days, certain endocrinological syndroms, the period of physiological activity of the thymus up through the time of sexual maturation including, in this period of life the preparation may be used only with evident immunological deficits.
Side Effects: No side effects are known. At the injection site an erythema and/or slight sensitivity may develop. If this occurs a one are two day break in the treatment is indicated.
Interaction: As an hormonal drug TFX-THYMOMODULIN ® may show synergism with certain pituitary hormone, somatotropin luteinizing hormone, and/or estrogens. It may antagonize adrenocortical hormones, progetserones and androgenes in their effectiveness on the lymphatic system and bone marrow.
Dosage: The dosage needs to be determined on an individual basis depending on the health of the patient. The following dosage is recommended: 10-20 mg/day for 30 days followed by 20-50 mg/week. Continued administration, the dosage, the duration of the treatment depend on the therapeutic effect and the immunological results.
Application: The preparation can be administered with subcutaneous or intramuscular injections. Dissolve TFX-THYMOMODULIN ® in 2 ml normal saline. Use immediately.
Warning: Store in a dry place. Do not use after expiration date. Do not use opened injection vials or previously dissolved solution.
Package Size: 1 original package of TFX-THYMOMODULIN ® contains 10, 10 mg injection vials of the lyophilisate and 10 ampoules of solvent.